MedPage Today news story
Use of the antidepressant mirtazapine in routine clinical practice reduced methamphetamine use in adults with methamphetamine use disorder, a phase III randomized trial showed.
In participants who used methamphetamine a median of 24 days over the past 28 days, the mean reduction in days of methamphetamine use from baseline to week 12 was greater in the mirtazapine group than in the placebo group (7 vs 4.8 days of 28 days, P=0.02), reported Rebecca McKetin, PhD, of the National Drug and Alcohol Research Centre at the University of New South Wales Sydney in Australia, and colleagues in JAMA Psychiatry.
There were no significant effects on secondary endpoints, including depression, insomnia, HIV risk behavior, quality of life, and methamphetamine-negative oral fluid samples.
Read the full news story here.
/free registration is required/
Source : MedPage Today
Related HIV and Co-Infections News
-
[Press release] NIH: Clinical trial results support use of weekly extended-release buprenorphine for treatment of opioid use disorder during pregnancy
-
HIV i-Base: GLP-1 receptor agonists reduce substance use disorder: a role for addiction to chemsex drugs?
-
UNAIDS: Decriminalization of drug use in the context of HIV: a guidance note
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.